Clinical Trial Detail

NCT ID NCT02703714
Title Pembrolizumab and GM-CSF in Biliary Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Robin Kate Kelley
Indications

biliary tract cancer

Therapies

Pembrolizumab + Sargramostim

Age Groups: adult

No variant requirements are available.